CBT-300

N/A

Report date: 2024/02/26 11:15:20

Base Information

Drug NameCBT-300
Drug Alias NameCBT-300CBT300
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of Action78 kDa glucose-regulated protein inhibitors
Targets78 kDa glucose-regulated protein
Therapy Area/IndicationsInfluenza A virus infectionsCoronavirus Disease 2019 (COVID-19)Alzheimer Disease +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCreative Biotherapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesCreative Biotherapeutics LLC
Inactive CompaniesN/A
Active IndicationsInfluenza A virus infectionsCoronavirus Disease 2019 (COVID-19)Alzheimer Disease +[14] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A